Elevated mepolizumab levels in patients with severe asthma responsive to 1 year’s mepolizumab treatment

Elevated mepolizumab levels in patients with severe asthma responsive to 1 year’s mepolizumab treatment

Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids. However, patients with severe asthma may require biologics, such as mepolizumab,...

全面介绍

书目详细资料
Main Authors: Takayasu Nishimaki, MD, Hitoshi Sasano, MD, PhD, Sonoko Harada, PhD, Tomohito Takeshige, MD, PhD, Yuuki Sandhu, MD, PhD, Yuki Tanabe, MD, Kei Matsuno, MD, PhD, Tetsutaro Nagaoka, MD, PhD, Jun Ito, MD, PhD, Ryo Atsuta, MD, PhD, Mayu Ohuchi, PhD, Shigehiro Yagishita, MD, PhD, Akinobu Hamada, PhD, Kazuhisa Takahashi, MD, PhD, Norihiro Harada, MD, PhD
格式: 文件
语言:English
出版: Elsevier 2025-05-01
丛编:Journal of Allergy and Clinical Immunology: Global
主题:
Asthma
mepolizumab
concentration
在线阅读:http://www.sciencedirect.com/science/article/pii/S2772829325000116

因特网

http://www.sciencedirect.com/science/article/pii/S2772829325000116

相似书籍